ClinicalTrials.gg
CompletedNCT03519243Updated Mar 4, 2021Results posted

Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis

A Phase 2 interventional study of BCD-131 and Mircera in Anemia, sponsored by Biocad. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-04.

Sponsored by Biocad · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Oct 2017, registered Apr 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Anemia with a site in Russian Federation — 1 open to participants now, 2 under way, 1 of them phase 3. Anemia · Russian Federation.

Enrollment
43rd of 51
75 · median 311
Started
2017
with 3 others
Phase 2
12 of 54
none open now
Registered
48th of 54
by date
Lead sponsor
2 of 54
Biocad

Among the 54 studies in Anemia with a site in Russian Federation, this one is the 43rd largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2017, is one of 12 in phase 2, and was the 48th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 54 studies in Anemia with a site in Russian Federation is open now. Recruiting first, the newest first:

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Anemia with a site in Russian Federation, or all of them as a file.
02

Study summary

BCD-131 is pegylated darbepoetin beta. BCD-131-2 is International Multicenter Randomized Open-Label Comparative Study (Phase II) of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis.

Read the detailed description

The hypothesis of the study is that the efficacy of BCD-131 is equivalent to that of Mircera® based on the analysis of the primary endpoint (changes in the Hb level over the period of evaluation as compared to the baseline Hb level ) during the 21-week period of treatment.

This study is a study of the maintenance treatment of anemia. The study will include up to 100 dialysis patients with stage 5D chronic kidney disease, established efficacy of dialysis and renal anemia without other causes of anemia, receiving erythropoiesis-stimulating agents (ESA) and reaching target hemoglobin levels.

03

Conditions studied

  • Anemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written .
  • Men and women aged from 18 to 75 years (inclusive) on the day of signing informed consent;
  • End-stage kidney disease.
  • Need for dialysis for at least 3 months before signing informed consent.
  • Need for at least 12 hours on standard dialysis procedure weekly.
  • rHuEpo (epoetin alpha, epoetin beta, darbepoetin alpha) administration for at least 3 months before signing informed consent.
  • Regular rHuEpo (epoetin alfa, epoetin beta, darbepoetin alfa) administration 1, 2 or 3 times a week (stable dose, stable frequency) before signing informed consent.
  • Target level (100-120 g/l) for at least 3 months before signing informed consent.
  • Effective dialysis dose index (Kt/v) ≥1.2 for patients receiving hemodialysis and (Kt/v) ≥1.7 for patients receiving peritoneal dialysis.
  • TSAT ≥20%, Serum ferritin >200 ng/ml.
  • Patients and their sexual partners with must implement reliable measures during all the study treatment, starting 4 weeks prior to the administration of the first dose of product until 4 weeks after the last dose of investigational product. This requirement does not apply to participants who have undergone surgical sterilization. Reliable contraceptive measures include two methods of contraception, including one barrier method/
  • Patients should be able to follow the Protocol procedures

Exclusion criteria

Exclusion Criteria:

  • Any other causes of anemia except for renal anemia, including folate and B12 deficiency, chronic blood loss, aluminium intoxication, sickle-cell anemia, chronic disease anemia (CRP above 20 mg/l), anemia with blast cells in peripheral blood.
  • Lupus nephritis of kidney disease due to systemic vasculitis.
  • count below 100х10\^9 cells/l.
  • Scheduled kidney transplant during study participation period.
  • to darbepoetin alfa or of any components of study drugs, or to Fe (III)-hydroxide-sucrose complex.
  • Vaccination less than 8 weeks before signing .
  • Liver cirrhosis with portal hypertension and/or splenomegaly and/or ascitis.
  • infection, active , .
  • , AST level above 3x .
  • Congestive heart failure (Grade IV )
  • Resistant arterial hypertension.
  • Unstable angina.
  • Hemoglobinopathy, MDS, hematologic , PRCA.
  • Severe secondary hyperparathyroidism.
  • Gastrointestinal bleeding history.
  • Thrombotic events history (myocardial infarction, stroke, , DVT, PATE) less than 6 months before signing informed consent.
  • Seizures, including epilepsy.
  • Major surgery in less than 1 month before signing informed consent
  • Blood transfusions in less than 3 months before signing informed consent.
  • Acute inflammatory diseases or exacerbations of chronic inflammation.
  • Severe psychiatric disorders and suicidal ideation and suicidal behavior.
  • History of malignancy, excluding appropriately treated basal cell carcinoma or cervical carcinoma in situ.
  • Alcohol or drug abuse.
  • Simultaneous participation in other trials or in less than 3 months before signing informed consent
  • Pregnancy of breast-feeding.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    BCD-131 1,05 mcg/kg * conversion ratio

    subcutaneously monthly

    Biological: BCD-131

  • Experimental
    BCD-131 1,7 mcg/kg * conversion ratio

    subcutaneously monthly

    Biological: BCD-131

  • Experimental
    BCD-131 2,75 mcg/kg * conversion ratio

    Subcutaneously monthly

    Biological: BCD-131

  • Active comparator
    Mircera

    subcutaneously monthly

    Biological: Mircera

Interventions

  • BiologicalBCD-131

    subcutaneously monthly

    Also known as: pegylated darbepoetin beta

  • BiologicalMircera

    subcutaneously monthly

    Also known as: Methoxy polyethylene glycol-epoetin beta

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period

    The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.

    Time frame: Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23

Secondary outcomes

  1. The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131

    The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131 - the proportion of patients, in each group, who discontinued the study due to AEs/SAEs

    Time frame: Week 23

  2. The Proportion of BAb- and NAb-positive Patients

    Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23. The immunogenicity endpoints will be analyzed after the completion of all periods of the study.

    Time frame: Week 9, 23

  3. AUC(0-672 Hour)

    Area under the concentration curve from the moment of injection to 672 h \[28 days\])

    Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1

  4. AUC(0-∞)

    Area under the concentration curve from the moment of injection to infinity

    Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21

  5. Cmax

    Maximum serum concentration of the drug product) after the first injection of the test/reference drug

    Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21

  6. AUEC(0-672 Hour)

    Area under the effect curve from the drug injection to 672 h \[28 days\]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug

    Time frame: 3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1

  7. AC-Emax

    Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®

    Time frame: day 28

07

Results

Posted Jul 26, 2019

Participant flow

Participant flow — Overall Study
MilestoneBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioBCD-131 2,75 mcg/kg * Conversion RatioMircera
Started2525025
Completed2021024
Not completed5401

Outcome measures

PrimaryChange in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period

The baseline hemoglobin will be calculated as the arithmetic mean of hemoglobin values obtained at screening and at Visit 1. The final hemoglobin value during the evaluation period will be calculated as the arithmetic mean of hemoglobin values obtained at Week 21 and Week 23.

Time frame:
Baseline - measurements on Screening (weeks -4 - 0) and on day 1; Evaluation period - weekly measures on weeks 21 to 23
Reported as:
Median · g/L
Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period
g/LBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
Change in Hemoglobin (Hb) Concentration From Baseline to the Evaluation Period-3.25 (-12 to 0.5)3.5 (-7 to 14)-2.75 (-9.5 to 9)
SecondaryThe Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131

The proportion of patients, in each group, who developed СТСАЕ v. 4.03 Grade 3-4 AEs that, in the Investigator's opinion, are related to BCD-131 - the proportion of patients, in each group, who discontinued the study due to AEs/SAEs

Time frame:
Week 23
Reported as:
Count of participants · Participants
The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131
ParticipantsBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
The Proportion of Patients Who Developed AEs/SAEs That, in the Investigator's Opinion, Are Related to BCD-131522
SecondaryThe Proportion of BAb- and NAb-positive Patients

Blood sampling for immunogenicity assessment (BAbs and NAbs) will be performed in all the patients included in the study before the first injection and then at Week 9 and Week 23. The immunogenicity endpoints will be analyzed after the completion of all periods of the study.

Time frame:
Week 9, 23
Reported as:
Count of participants · Participants
The Proportion of BAb- and NAb-positive Patients
ParticipantsBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
The Proportion of BAb- and NAb-positive Patients000
SecondaryAUC(0-672 Hour)

Area under the concentration curve from the moment of injection to 672 h \[28 days\])

Time frame:
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
Reported as:
Median · (mmol/L)*h
AUC(0-672 Hour)
(mmol/L)*hBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
AUC(0-672 Hour)51744.45 (31201.8 to 87463.5)73948.8 (57057.15 to 133730.25)89409.3 (35389.95 to 166699.5)
SecondaryAUC(0-∞)

Area under the concentration curve from the moment of injection to infinity

Time frame:
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
Reported as:
Median · (mmol/L)*h
AUC(0-∞)
(mmol/L)*hBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
AUC(0-∞)65150.045 (43463.791 to 91305.66)81698.001 (63442.206 to 142665.693)96259.513 (46985.695 to 192570.672)
SecondaryCmax

Maximum serum concentration of the drug product) after the first injection of the test/reference drug

Time frame:
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1, weeks 5, 9, 13, 17, 21
Reported as:
Median · mmol/L
Cmax
mmol/LBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
Cmax195.3 (148.7 to 407.1)231.9 (187.2 to 488.2)617.6 (130.6 to 943.2)
SecondaryAUEC(0-672 Hour)

Area under the effect curve from the drug injection to 672 h \[28 days\]) based on the change in the absolute reticulocyte count after the first injection of the test/reference drug

Time frame:
3, 6, 12, 24, 48, 72, 96, 168, 336, 504, 672 h h after injection 1
Reported as:
Mean · (cells*10^9)*h
AUEC(0-672 Hour)
(cells*10^9)*hBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
AUEC(0-672 Hour)7210.479 ± 5465.15511274.380 ± 12460.17712131.820 ± 15613.087
SecondaryAC-Emax

Maximum absolute reticulocyte count after the first injection of BCD-131/Mircera®

Time frame:
day 28
Reported as:
Mean · (cells*10^9)/L
AC-Emax
(cells*10^9)/LBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
AC-Emax96.650 ± 29.185107.047 ± 38.615154.753 ± 58.729

Adverse events

Collected over 25 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BCD-131 1,05 mcg/kg * Conversion Ratio1/25 (4%)6/25 (24%)13/25 (52%)
BCD-131 1,7 mcg/kg * Conversion Ratio2/25 (8%)4/25 (16%)16/25 (64%)
Mircera0/25 (0%)3/25 (12%)15/25 (60%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
subcutaneous tissueSkin and subcutaneous tissue disorders1/250/250/25
consequence of strokeNervous system disorders1/250/250/25
fracture of the left ankleMusculoskeletal and connective tissue disorders1/250/250/25
Hemorrhagic strokeNervous system disorders1/250/250/25
Ischemic Heart DiseaseCardiac disorders1/250/250/25
non-Q wave myocardial infarctionCardiac disorders1/250/250/25
Arteriovenous Access ThrombosisVascular disorders0/251/251/25
myocardial infarctionCardiac disorders0/251/250/25
Type 2 diabetes. Diabetic foot syndromeEndocrine disorders0/251/250/25
Catheter-associated infectionInfections and infestations0/251/250/25
Most frequent other events
Most frequent other events
EventBCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMircera
hyperglycemiaInvestigations6/254/252/25
systolic blood pressure increase (isolated)Vascular disorders3/256/254/25
dyastolic blood pressure increase (isolated)Vascular disorders2/254/256/25
arterial pressure increaseVascular disorders4/253/253/25
lymphocytes decreaseInvestigations4/252/251/25
leukocytes decreaseInvestigations2/251/251/25
neutrophils decreaseInvestigations2/252/252/25
ECG changesCardiac disorders0/252/252/25
lymphocytes increaseInvestigations1/250/252/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)BCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMirceraTotal
Median60 (48 to 64)54 (46 to 63)47 (35 to 58)55 (46 to 63)
Sex: Female, Male
Sex: Female, Male(Participants)BCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMirceraTotal
Female14121137
Male11131438
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMirceraTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White24252473
More than one race0000
Unknown or Not Reported1012
Region of Enrollment
Region of Enrollment(participants)BCD-131 1,05 mcg/kg * Conversion RatioBCD-131 1,7 mcg/kg * Conversion RatioMirceraTotal
Belarus5128
Russia20242367
08

Study locations

3 sites
  • City Clinical Hospital №9
    Minsk, Belarus
  • City Mariin Hospital
    St. Petersburg, 194104, Russian Federation
  • B.Braun Avitum Russland Clinics Ltd.
    St.Petersburg, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Dec 2018, 13 months.

Results were first posted in Jul 2019, 7 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 13 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2018
First posted
May 8, 2018
StartActual
Oct 24, 2017
Primary completionActual
Dec 1, 2018
CompletionActual
Dec 10, 2018
Results first posted
Jul 26, 2019
Last update
Mar 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03519243
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
May 8, 2018
Start date
Oct 24, 2017
Primary completion
Dec 1, 2018
Completion
Dec 10, 2018
Results posted
Jul 26, 2019
Last update
Mar 4, 2021

Study contacts

Roman Ivanov, PhD
study chair · JCS BIOCAD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion